Norwegian Finans Holding ASA
Bank Norwegian AS refers to the announcement on 8 March 2021. The bank has today conducted buybacks in BANKN22 and BANKN23 with the following terms:
SEK 40 million in BANKN22 (ISIN NO0010848583) at 100.589 equal to 3 months STIBOR + 0.30%
NOK 381 million in BANKN23 (ISIN NO0010848591) at 101.048 equal to 3 months NIBOR + 0.50%
The settlement date is 18 March 2021. BANKN23 will be retained on the issuers own book. Outstanding amount in BANKN22 will be reduced with SEK 40 million to SEK 152 million.
Contact persons:
CFO Klara-Lise Aasen; phone +47 47 63 55 83; kaa@banknorwegian.no
Head of treasury Mats Benserud; phone +47 95 89 15 39; mbe@banknorwegian.no
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
